WA
Wanbury Ltd (WANBURY)
₹179.37
Mkt cap
₹676 Cr
P/E ratio
12.10
P/B
3.92
Div yield
0.00%
ROE
68.40%
ROCE
30.70%
EPS (TTM)
₹14.82
Book value
₹46
52W range
162–359
Sector
Healthcare
Price history
Previous close
Incorporated in 1988, Wanbury Ltd is in the business of pharmaceutical and related activities, including research [1]
NSE WANBURYBSE 524212
Health check
Constructive
ValuationCheap
ProfitabilityStrong
GrowthModerate
TechnicalsBearish
52-week range
−50.02% from high₹179
₹162+11.07% from low₹359
Current
₹179.37
Prev close
₹181.66
Day
−1.26%
Price performance
1D
−1.46%
1W
−7.47%
1M
−3.64%
3M
−33.33%
6M
−36.75%
1Y
−25.57%
YTD
−24.00%
Financials
Revenue, profit & margin
P/E ratio
12.1×
WANBURY is 64% below the sector median of 34.0×
WANBURY12.1×
Sector median34.0×
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 144 | 146 | 139 | 131 | 161 | 133 | 172 | 163 | 160 | 162 | 165 | 166 | 183 | |
| YoY Sales growth | +17% | +16% | +5% | -10% | +12% | -8% | +23% | +24% | -1% | +22% | -4% | +1% | +14% | |
| Expenses | 127 | 124 | 121 | 120 | 141 | 120 | 142 | 139 | 134 | 136 | 135 | 149 | 157 | |
| Operating Profit | 17 | 21 | 18 | 11 | 20 | 14 | 30 | 24 | 26 | 27 | 30 | 16 | 26 | |
| OPM % | 12% | 15% | 13% | 8% | 12% | 10% | 17% | 15% | 16% | 16% | 18% | 10% | 14% | |
| Other Income | 1 | 1 | 1 | 1 | 2 | 1 | 2 | 0 | 0 | 0 | -3 | 0 | 0 | |
| Interest | 8 | 8 | 7 | 8 | 10 | 10 | 9 | 8 | 7 | 7 | 8 | 8 | 6 | |
| Depreciation | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 3 | 4 | 4 | |
| Profit before tax | 7 | 10 | 8 | 1 | 8 | 1 | 19 | 14 | 15 | 16 | 15 | 5 | 16 | |
| Tax % | -2% | -0% | 3% | 0% | 2% | 5% | -6% | 1% | -0% | 1% | -43% | 29% | 24% | |
| Net Profit | 7 | 10 | 8 | 1 | 8 | 1 | 20 | 13 | 15 | 16 | 22 | 3 | 12 | |
| EPS in Rs | 2.25 | 3.14 | 2.47 | 0.32 | 2.45 | 0.37 | 6.18 | 4.10 | 4.35 | 4.52 | 6.21 | 0.93 | 3.40 | |
| Raw PDF |
Earnings
Results dates & reactionsNo upcoming results date on calendar.
Fresh quarters land in the Financials table above, tagged NSE until screener catches up.
Corporate actions
Last 6 monthsNo recent corporate actions
Dividends, splits, and bonuses in the last six months show up here.
Results analysis
Shareholding
as of Sep 202642.98%Promoter
Promoters42.98%0.03
FIIs0.71%0.18
DIIs0.02%0.04
Public56.28%0.24
Ownership trend
Peers
8 companiesValuation vs quality
P/E × ROCE · bubble = market cap| Name | CMP | P/E | Mkt Cap | Div Yld | NP Qtr | Qtr Profit Var | Sales Qtr | Qtr Sales Var | ROCE |
|---|---|---|---|---|---|---|---|---|---|
| Sun Pharma.Inds. | ₹1,880.00 | 36.66 | 4,51,075 | 0.85% | 1,995 | −10.53% | 16,199 | +11.88% | 20.53% |
| Divi's Lab. | ₹11,442.00 | 88.89 | 3,03,749 | 0.26% | 1,127 | +63.57% | 3,676 | +35.40% | 21.97% |
| Torrent Pharma. | ₹4,670.00 | 81.82 | 1,77,632 | 0.81% | 534 | −10.03% | 4,979 | +50.79% | 15.19% |
| Laurus Labs | ₹2,424.00 | 97.75 | 1,30,972 | 0.08% | 436 | +126.43% | 2,206 | +33.44% | 17.76% |
| Zydus Lifesci. | ₹1,189.90 | 26.20 | 1,18,693 | 0.08% | 928 | −27.96% | 7,910 | +29.17% | 21.14% |
| Dr Reddy's Labs | ₹1,380.00 | 41.17 | 1,15,267 | 0.58% | 913 | −31.35% | 8,698 | −1.48% | 13.04% |
| Cipla | ₹1,391.80 | 36.21 | 1,12,442 | 0.93% | 852 | −35.05% | 7,404 | −2.44% | 15.49% |
| Wanbury | ₹193.46 | 12.07 | 676 | 0.00% | 12 | −21.74% | 183 | +14.28% | 30.66% |
| Median: 160 Co. | ₹465.83 | 33.99 | 2,012 | 0.08% | 13 | +33.53% | 179 | +20.92% | 14.94% |
Filings
Annual reports15
Concall transcripts4
Credit ratings4
Announcements5
Announcement under Regulation 30 (LODR)-Press Release / Media Release 12 Nov - Wanbury received ANVISA CADIFA approval for Metformin HCl EP grade; third consecutive API approval.Announcement under Regulation 30 (LODR)-Press Release / Media Release 6 Nov - Wanbury reported Q2 FY27 revenue of Rs 182.9 crore and PAT of Rs 11.9 crore, plus approvals and launches.Board Meeting Outcome for Outcome Of The Board Meeting Held On November 04, 2026 4 Nov - Wanbury approved Q2 FY27 results; incorporated Wanbury Skin Health for dermatology and baby care.Financial Results As On 30Th September, 2026 4 Nov - Wanbury approved Q2 and H1 FY2027 results; formed Wanbury Skin Health subsidiary, commenced October 2026.Announcement under Regulation 30 (LODR)-Press Release / Media Release 30 Oct - Tanuku plant received Australian TGA GMP certificate on 28 October 2026, valid until 9 December 2028.






